Silvia Martu

Silvia Martu

Auto-generated profile, based on publicly available information

Silvia Martu

University of Medicine and Pharmacy “Gr.T.Popa”, Iasi, Romania

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Procedia - Social and Behavioral Sciences
Verified
Journal Article
Open access
GSGrigoras Simona
Grigoras Simona
MSMârtu Silvia
Mârtu Silvia
CBCarina Balcoş
Carina Balcoş
The purpose of this study was to assess the influence of periodontal disease on the quality of life in the adult population of Iasi, Romania. The study was conducted on 50 subjects aged between 24 and 68 years. The data have been gathered using clinical exams according to the WHO criteria, while for the quality of life evaluation the subjects completed the OHIP-14 questionnaire. According to the results of the study, the most affected OHIP dimensions found to be: “psychological discomfort”,“functional limitation” and “physical pain” among the patients, while the higher OHIP scores were recorded in patients with aggressive periodontitis. The study concluded that the periodontal disease can affect the quality of life, especially of those patients suffering from aggressive periodontitis

15 March 2024 in Romanian Journal of Oral Rehabilitation
Verified
Journal Article
Open access
BVBogdan-Constantin Vasiliu
Bogdan-Constantin Vasiliu
Maria-Alexandra MartuMaria-Alexandra Martu
Maria-Alexandra Martu
Irina SufaruIrina Sufaru
Irina Sufaru
GMGeorge-Alexandru Maftei
George-Alexandru Maftei
IMIoana Martu
Ioana Martu
SMSilvia Martu
Silvia Martu
Chronic periodontitis is a disease caused by several factors; therefore, it can be called a multifactorial disease. Such risk factors include smoking, diabetes, genetics, depression, and stress. Depression is one of the chronic conditions with the highest prevalence worldwide. There is evidence to support the association between psychological disorders and the physiological and behavioral precursors of caries and periodontal disease, suggesting that such a connection may exist. Antidepressant and anxiolytic medication have been associated with decreased salivary flow and poor oral hygiene. The present study aimed to examine the local inflammatory status of patients with periodontal disease and no other systemic conditions and patients with periodontal disease and depression. Between February 2024 and March 2024, we conducted this study on 40 patients aged 20 and 48, evaluating the Quigley Hein Plaque Index, the GI Index of Löe and Silness, and the PBI Index. Analyzing the obtained results, we observed that the values of the periodontal parameters, such as the hygiene index, the gingival inflammation index, and the papillary bleeding index, were significantly higher in the group of patients with periodontal disease and depression compared to the group of patients with only periodontal disease.

29 December 2025 in Romanian Journal of Oral Rehabilitation
Verified
Journal Article
Closed access
Irina SufaruIrina Sufaru
Irina Sufaru
LPLiliana Pasarin
Liliana Pasarin
Maria-Alexandra MartuMaria-Alexandra Martu
Maria-Alexandra Martu
DTDiana Tatarciuc
Diana Tatarciuc
SSSorina Mihaela Solomon
Sorina Mihaela Solomon
IMIoana Martu
Ioana Martu
Background: Osteoporosis and periodontitis are prevalent chronic conditions in aging populations and are both characterized by bone loss in distinct anatomical compartments. Increasing attention has focused on inflammation as a potential biological link between systemic skeletal deterioration and periodontal breakdown. Objective: This narrative review summarizes inflammatory mechanisms that may link osteoporosis (or low bone mineral density) with periodontal status and critically appraises the clinical evidence supporting these associations. Summary of evidence: Osteoporosis, particularly in postmenopausal and older individuals, is increasingly understood within an osteoimmune framework in which low-grade systemic inflammation contributes to remodeling imbalance. Cytokine networks and immune cell–mediated signaling can promote osteoclastogenesis and weaken coupling between resorption and formation. Periodontitis is driven by a dysbiosis-associated, non-resolving host response that sustains local inflammation and favors connective tissue degradation and alveolar bone resorption. Convergent pathways include upregulation of osteoclastogenic signals (notably RANKL/OPG imbalance), cytokine amplification loops, and adaptive immune polarization that may lower the threshold for destructive inflammation. Clinically, observational studies frequently report worse periodontal parameters in individuals with osteoporosis or low bone mineral density, with signals often more apparent in postmenopausal cohorts. Nonetheless, heterogeneity in phenotype definitions, residual confounding, and the predominance of cross-sectional designs limit causal inference; genetic causal-inference studies generally argue against a strong direct causal effect of bone mineral density on periodontitis risk. Conclusions: The most defensible interpretation is a modifier model: systemic skeletal status and osteoporosis-related inflammatory tone may influence susceptibility to periodontal breakdown or its progression once local dysbiosis-driven inflammation is established. Future work should prioritize standardized periodontal phenotyping, progression-focused longitudinal designs, and the integration of inflammatory and bone-turnover biomarkers, while accounting for menopausal stage and medication exposure.

15 March 2024 in Romanian Journal of Oral Rehabilitation
Verified
Journal Article
Open access
GLGeorgeta-Maria Laza
Georgeta-Maria Laza
Maria-Alexandra MartuMaria-Alexandra Martu
Maria-Alexandra Martu
Irina SufaruIrina Sufaru
Irina Sufaru
SMSilvia Martu
Silvia Martu
LPLiliana Pasarin
Liliana Pasarin
IMIoana Martu
Ioana Martu
Patients with osteoporosis exhibit a nearly twofold higher diagnosis rate of periodontitis compared to the general population, indicating osteoporosis is a potentially significant risk factor for periodontitis development. This study explored changes in periodontal and radiological parameters after systemic alendronate use in osteoporotic patients with periodontal disease. Sixty-four post-menopausal adults diagnosed with osteoporosis and periodontal disease were divided into two groups: Group A, without bisphosphonate therapy, and Group B, receiving alendronate (70mg/week) for 12 months. Both groups underwent non-surgical periodontal treatment. Parameters including plaque index (PI), bleeding on probing (BOP), probing depth (PD), clinical attachment loss (CAL), and radiographic infrabony defect depth (IBD) were evaluated at baseline and after 12 months. Oral administration of alendronate at 70 mg/week for 12 months was found to be safe and effective in enhancing the outcomes of non-surgical periodontal therapy both clinically and radiologically. This suggests alendronate could be a valuable adjunctive treatment for managing periodontal disease in osteoporotic patients

29 December 2025 in Romanian Journal of Oral Rehabilitation
Verified
Journal Article
Closed access
Irina SufaruIrina Sufaru
Irina Sufaru
IMIoana Martu
Ioana Martu
LPLiliana Pasarin
Liliana Pasarin
Maria-Alexandra MartuMaria-Alexandra Martu
Maria-Alexandra Martu
DTDiana Tatarciuc
Diana Tatarciuc
SSSorina Mihaela Solomon
Sorina Mihaela Solomon
Metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH) are now defined by clear metabolic criteria, with current approaches emphasizing fibrosis risk due to its impact on liver-related outcomes. Periodontitis is a common chronic inflammatory disease caused by dysbiotic subgingival biofilms and sustained by an exaggerated host response. This narrative review consolidates clinical and experimental evidence connecting periodontitis to MASLD/MASH through the oral–gut–liver axis. Epidemiologic studies frequently observe the co-occurrence of periodontitis and steatotic liver disease, and several cohorts indicate dose–response patterns when periodontal severity correlates with fibrosis-related liver outcomes like elastography or validated non-invasive fibrosis scores. However, these associations are inconsistent and tend to diminish when adjusting for strongly related factors such as obesity, diabetes, smoking intensity, diet, socioeconomic status, and healthcare utilization. Interpretation is also constrained by differing case definitions, various liver outcomes (such as imaging-detected steatosis, aminotransferases, fibrosis scores, elastography, biopsy), and possible reverse causality. Mechanistic plausibility is supported by several converging pathways: intermittent systemic spread of bacteria and microbial products (including LPS) from periodontal pockets; oral-to-gut microbial transmission causing ecological changes in the intestinal microbiome; intestinal barrier dysfunction leading to increased portal delivery of endotoxin and metabolites; and activation of hepatic innate immunity that enhances lipotoxic stress, oxidative injury, inflammasome signaling, and stellate-cell–mediated fibrogenesis. In obesity-prone models, induced periodontitis worsens steatotic liver phenotypes and highlights manageable targets such as TLR pathways and microbiota-dependent tryptophan–AHR signaling. Clinically, the most justified implication is integrated risk recognition rather than definitive causal claims. Dental teams can start metabolic evaluation and fibrosis risk assessment for high-risk patients, while hepatology and metabolic clinics can include brief oral screenings and periodontal referrals. Future priorities include standardizing phenotyping, conducting repeated-measure cohort studies, and running periodontal intervention trials with fibrosis-related endpoints. Using multi-omics and causal frameworks will be crucial for translating research into clinical practice.

29 December 2025 in Romanian Journal of Oral Rehabilitation
Verified
Journal Article
Closed access
Irina SufaruIrina Sufaru
Irina Sufaru
IMIoana Martu
Ioana Martu
DTDiana Tatarciuc
Diana Tatarciuc
Maria-Alexandra MartuMaria-Alexandra Martu
Maria-Alexandra Martu
SMSilvia Martu
Silvia Martu
LPLiliana Pasarin
Liliana Pasarin
Background: Cardiovascular disease and periodontitis commonly coexist, and cardiovascular pharmacotherapy may affect periodontal tissues and clinical indices, thereby influencing treatment planning. Objective: To synthesize clinically relevant associations between major cardiovascular medication classes and periodontal status and to translate these findings into practical considerations for periodontal care. Summary of evidence: Calcium channel blockers provide the most consistent signal, with a strong association with drug-induced gingival overgrowth. Enlargement can promote pseudo-pocketing, impair plaque control, and intensify gingival inflammation; expression is modified by local biofilm burden and supportive periodontal care. Statins show a plausible host-modulatory signal; observational studies and adjunctive trials report improvements in inflammatory parameters and, in selected settings, modest additional reductions in probing depth and clinical attachment gain, but heterogeneity and risk of bias limit certainty. Evidence for ACE inhibitors/angiotensin receptor blockers, beta-blockers, and diuretics is limited and often mediated by xerostomia, frailty, and oral health behaviors. Antiplatelet and anticoagulant therapy mainly affects bleeding-based indices; increased bleeding on probing does not necessarily indicate greater attachment loss. Polypharmacy can amplify xerostomia and complicate home care, while bleeding-based indices may be misleading without concurrent attachment and radiographic endpoints for assessment. Conclusions: Cardiovascular medications can alter periodontal presentation and complicate longitudinal monitoring. Medication-aware history taking (agent, dose, duration, combinations), interpretation anchored in attachment and bone measures, and tailored management of gingival overgrowth, bleeding risk, and xerostomia are recommended. Future research should apply standardized periodontal outcomes and detailed exposure definitions in longitudinal designs and, in pragmatic trials, evaluate whether optimized periodontal care in cardiovascular-medicated patients improves systemic inflammatory and vascular biomarkers.